Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM.

Cancer Metab. 2018 Apr 3;6:3. doi: 10.1186/s40170-018-0178-3. eCollection 2018.

2.

In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.

Wenger KJ, Hattingen E, Franz K, Steinbach J, Bähr O, Pilatus U.

Clin Neuroradiol. 2019 Mar;29(1):27-36. doi: 10.1007/s00062-017-0630-8. Epub 2017 Oct 5.

PMID:
28983683
3.

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM.

Cancer Res. 2018 May 1;78(9):2290-2304. doi: 10.1158/0008-5472.CAN-17-2926. Epub 2018 Jan 22.

PMID:
29358170
4.

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.

Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM.

Neuroimage Clin. 2016 Jun 23;12:180-9. doi: 10.1016/j.nicl.2016.06.018. eCollection 2016.

5.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM.

J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.

6.

A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy.

Shen X, Voets NL, Larkin SJ, de Pennington N, Plaha P, Stacey R, McCullagh JSO, Schofield CJ, Clare S, Jezzard P, Cadoux-Hudson T, Ansorge O, Emir UE.

Metabolites. 2019 Feb 20;9(2). pii: E35. doi: 10.3390/metabo9020035.

7.

IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.

Leu S, von Felten S, Frank S, Boulay JL, Mariani L.

J Neurooncol. 2016 Apr;127(2):363-72. doi: 10.1007/s11060-015-2048-y. Epub 2016 Jan 16.

PMID:
26780338
8.

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.

Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E.

Neuro Oncol. 2016 Nov;18(11):1559-1568. Epub 2016 May 5.

9.

Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.

Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper RO, Phillips JJ, Ronen SM.

PLoS One. 2014 Sep 22;9(9):e108289. doi: 10.1371/journal.pone.0108289. eCollection 2014.

10.

IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Esmaeili M, Hamans BC, Navis AC, van Horssen R, Bathen TF, Gribbestad IS, Leenders WP, Heerschap A.

Cancer Res. 2014 Sep 1;74(17):4898-907. doi: 10.1158/0008-5472.CAN-14-0008. Epub 2014 Jul 8.

11.

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.

Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB.

Neuro Oncol. 2012 Dec;14(12):1465-72. doi: 10.1093/neuonc/nos258. Epub 2012 Oct 22.

12.

Metabolic reprogramming in mutant IDH1 glioma cells.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen SM.

PLoS One. 2015 Feb 23;10(2):e0118781. doi: 10.1371/journal.pone.0118781. eCollection 2015.

13.

Combination genetic signature stratifies lower-grade gliomas better than histological grade.

Chan AK, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Wang Y, Zhou L, Ng HK.

Oncotarget. 2015 Aug 28;6(25):20885-901.

14.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.

Oncotarget. 2015 Oct 6;6(30):30295-305. doi: 10.18632/oncotarget.4497.

15.

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM.

Cancer Res. 2015 Aug 1;75(15):2999-3009. doi: 10.1158/0008-5472.CAN-15-0840. Epub 2015 Jun 4.

16.

Phospholipid biosynthetic enzymes in human brain.

Ross BM, Moszczynska A, Blusztajn JK, Sherwin A, Lozano A, Kish SJ.

Lipids. 1997 Apr;32(4):351-8.

PMID:
9113621
17.
18.

Mutant IDH1 and thrombosis in gliomas.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C.

Acta Neuropathol. 2016 Dec;132(6):917-930. Epub 2016 Sep 23.

19.

Lactate dehydrogenase A silencing in IDH mutant gliomas.

Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA, Cairncross JG.

Neuro Oncol. 2014 May;16(5):686-95. doi: 10.1093/neuonc/not243. Epub 2013 Dec 22.

20.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5.

PMID:
24590270

Supplemental Content

Support Center